

PRODUCT MONOGRAPH  
INCLUDING PATIENT MEDICATION INFORMATION

Pr **CONSTELLA<sup>®</sup>**

Linaclotide

Capsules of 72 mcg, 145 mcg and 290 mcg linaclotide, for oral use

Guanylate Cyclase-C Agonist (ATC Code: A06AX04)

Allergan Inc.  
85 Enterprise Blvd., Suite 500  
Markham, Ontario  
L6G 0B5

Date of Initial Authorization:  
DEC 02, 2013

Date of Revision:  
JUL 26, 2022

Submission Control Number: 261787

## RECENT MAJOR LABEL CHANGES

7 WARNINGS AND PRECAUTIONS, <a href="#">7.1.2 Breast-feeding</a>	07/2022
--	---------

## TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

<b>RECENT MAJOR LABEL CHANGES .....</b>	<b>2</b>
<b>TABLE OF CONTENTS .....</b>	<b>2</b>
<b>PART I: HEALTH PROFESSIONAL INFORMATION .....</b>	<b>4</b>
<b>1 INDICATIONS .....</b>	<b>4</b>
1.1 Pediatrics .....	4
1.2 Geriatrics.....	4
<b>2 CONTRAINDICATIONS .....</b>	<b>4</b>
<b>3 SERIOUS WARNINGS AND PRECAUTIONS BOX .....</b>	<b>4</b>
<b>4 DOSAGE AND ADMINISTRATION .....</b>	<b>5</b>
4.1 Dosing Considerations .....	5
4.2 Recommended Dose and Dosage Adjustment.....	5
4.4 Administration.....	5
4.5 Missed Dose .....	6
<b>5 OVERDOSAGE .....</b>	<b>6</b>
<b>6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING .....</b>	<b>7</b>
<b>7 WARNINGS AND PRECAUTIONS .....</b>	<b>7</b>
7.1 Special Populations.....	8
7.1.1 Pregnant Women.....	8
7.1.2 Breast-feeding.....	8
7.1.3 Pediatrics .....	8
7.1.4 Geriatrics .....	8
<b>8 ADVERSE REACTIONS .....</b>	<b>8</b>
8.1 Adverse Reaction Overview.....	8
8.2 Clinical Trial Adverse Reactions .....	9
8.3 Less Common Clinical Trial Adverse Reactions .....	12
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other	

	Quantitative Data.....	13
	8.5 Post-Market Adverse Reactions.....	13
<b>9</b>	<b>DRUG INTERACTIONS.....</b>	<b>13</b>
	9.2 Drug Interactions Overview.....	13
	9.3 Drug-Behavioural Interactions.....	13
	9.4 Drug-Drug Interactions .....	13
	9.5 Drug-Food Interactions .....	13
	9.6 Drug-Herb Interactions .....	13
	9.7 Drug-Laboratory Test Interactions.....	13
<b>10</b>	<b>CLINICAL PHARMACOLOGY .....</b>	<b>14</b>
	10.1 Mechanism of Action.....	14
	10.2 Pharmacodynamics .....	14
	10.3 Pharmacokinetics.....	16
<b>11</b>	<b>STORAGE, STABILITY AND DISPOSAL .....</b>	<b>17</b>
<b>12</b>	<b>SPECIAL HANDLING INSTRUCTIONS.....</b>	<b>17</b>
	<b>PART II: SCIENTIFIC INFORMATION .....</b>	<b>18</b>
<b>13</b>	<b>PHARMACEUTICAL INFORMATION.....</b>	<b>18</b>
<b>14</b>	<b>CLINICAL TRIALS.....</b>	<b>19</b>
	14.1 Clinical Trials by Indication.....	19
	Irritable Bowel Syndrome with Constipation (IBS-C) .....	19
	Chronic Idiopathic Constipation (CIC).....	27
<b>15</b>	<b>MICROBIOLOGY .....</b>	<b>34</b>
<b>16</b>	<b>NON-CLINICAL TOXICOLOGY .....</b>	<b>34</b>
	<b>PATIENT MEDICATION INFORMATION .....</b>	<b>37</b>

## PART I: HEALTH PROFESSIONAL INFORMATION

### 1 INDICATIONS

CONSTELLA (linaclotide capsules) is indicated for:

- The treatment of irritable bowel syndrome with constipation (IBS-C) in adults.
- The treatment of chronic idiopathic constipation (CIC) in adults.

The efficacy of CONSTELLA for the treatment of IBS-C and CIC has been established in double-blind, placebo-controlled studies of up to 26 and 12 weeks duration, respectively (see [14 CLINICAL TRIALS](#)).

#### 1.1 Pediatrics

CONSTELLA is contraindicated in children under 6 years of age and is not recommended for use in children between 6 and 18 years of age as the safety and efficacy of CONSTELLA in pediatric patients have not been established. See [2 CONTRAINDICATIONS](#), [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#), [7.1.3 Pediatrics](#) and [16 NON-CLINICAL TOXICOLOGY](#).

#### 1.2 Geriatrics

**Irritable Bowel Syndrome with Constipation:** Of 1,605 IBS-C patients in the placebo-controlled clinical studies of CONSTELLA, 85 (5%) were at least 65 years of age, while 20 (1%) were at least 75 years old. Clinical studies of CONSTELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

**Chronic Idiopathic Constipation:** Of 2,498 CIC patients in the placebo-controlled clinical studies of CONSTELLA, 273 (11%) were at least 65 years of age, while 56 (2%) were at least 75 years old. Clinical studies of CONSTELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

### 2 CONTRAINDICATIONS

CONSTELLA is contraindicated in:

- pediatric patients under 6 years of age. See [7.1.3 Pediatrics](#).
- patients who are hypersensitive to linaclotide or to any ingredient in the formulation or component of the container. For a complete listing see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#).
- patients with known or suspected mechanical gastrointestinal obstruction.

### 3 SERIOUS WARNINGS AND PRECAUTIONS BOX

#### Serious Warnings and Precautions

CONSTELLA is contraindicated in children up to 6 years of age and is not recommended in children between 6 and 18 years of age. See [2 CONTRAINDICATIONS](#), [7.1.3 Pediatrics](#), [16 NON-CLINICAL TOXICOLOGY](#).

## 4 DOSAGE AND ADMINISTRATION

### 4.1 Dosing Considerations

Patients should be counselled that improvement of bowel symptoms should occur within the first week of CONSTELLA treatment, but improvement of abdominal symptoms may take longer (see [14 CLINICAL TRIALS](#)). Physicians should periodically assess the need for continued treatment with CONSTELLA.

Patients on treatment who experience severe diarrhea should stop CONSTELLA and contact their physician (see [7 WARNINGS AND PRECAUTIONS](#)).

Exceeding the daily dose of 145 mcg for the treatment of CIC is not expected to increase efficacy.

### 4.2 Recommended Dose and Dosage Adjustment

#### Irritable Bowel Syndrome with Constipation

The recommended dose of CONSTELLA is 290 mcg taken orally once daily on an empty stomach, at least 30 minutes prior to the first meal of the day. See [10.3 Pharmacokinetics](#).

#### Chronic Idiopathic Constipation

The recommended dose of CONSTELLA is 145 mcg taken orally once daily on an empty stomach, at least 30 minutes prior to the first meal of the day. See [10.3 Pharmacokinetics](#). A dose of 72 mcg may be used depending on individual clinical presentation or response to the starting dose.

#### Special Populations

No dose adjustments are required for patients with hepatic or renal impairment. See [10.3 Pharmacokinetics](#).

Health Canada has not authorized an indication for pediatric use. See [2 CONTRAINDICATIONS](#) and [7.1.3 Pediatrics](#).

### 4.4 Administration

CONSTELLA capsules should be taken orally once daily on an empty stomach, at least 30 minutes prior to the first meal of the day. The capsules should be swallowed whole and should not be chewed. For adult patients who have difficulty swallowing, the contents of the capsules may be given in applesauce or water. Sprinkling of CONSTELLA beads on other soft foods or in other liquids has not been tested.

For administration in applesauce:

- Place one teaspoonful of applesauce at room temperature into a clean container.
- Open the capsule.
- Sprinkle entire contents (beads) on applesauce.
- Consume the contents immediately. Do not chew the beads. Do not store the applesauce and beads for later use.

For administration in water:

- Pour approximately 30 mL of bottled water at room temperature into a clean cup.
- Open the capsule.

- Sprinkle entire contents (beads) into the water.
- Gently swirl beads and water for at least 20 seconds.
- Swallow the mixture of beads and water immediately.
- Add another 30 mL of water to any beads remaining in the cup, swirl for 20 seconds and swallow immediately.
- Do not store the bead-water mixture for future use.

Note: The drug is coated on the surface of the beads and will dissolve off the beads into the water. The beads will remain visible and will not dissolve. Therefore, it is not necessary to consume all of the beads to deliver the complete dose.

For nasogastric or gastric feeding tube administration in water:

- Open the capsule and empty the beads into a clean container with 30 mL of room temperature bottled water.
- Mix by gently swirling beads for at least 20 seconds.
- Draw up the bead-water mixture into an appropriately sized catheter-tipped syringe and apply rapid and steady pressure (10 mL / 10 seconds) to dispense the syringe contents into the tube.
- After administering the bead-water mixture, flush the nasogastric / gastric tube with a minimum of 10 mL of water.
- Add another 30 mL of water to the container and repeat the process.
- Use the mixture of beads and water immediately. Do not store for future use.

Note: It is not necessary to flush all of the beads through to deliver the complete dose.

The first meal of the day can be consumed 30 minutes after dosing of CONSTELLA.

#### **4.5 Missed Dose**

In the event that a dose is missed, the patient should skip that dose. Do not take two capsules to account for the missed dose. Wait until it is time for the next dose and then take the usual dose on an empty stomach.

### **5 OVERDOSAGE**

There is limited experience with overdose of CONSTELLA. During the clinical development program of CONSTELLA, single doses of 2897 mcg were administered to 22 healthy volunteers; the safety profile in these subjects was consistent with that in the overall CONSTELLA-treated population, with diarrhea being the most commonly reported adverse reaction.

For management of a suspected drug overdose, contact your regional poison control centre.

## 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

**Table 1 – Dosage Forms, Strengths, Composition and Packaging**

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	Capsules 145 mcg, 290 mcg	calcium chloride dihydrate, gelatin, hypromellose, iron oxide black, iron oxide yellow, L-leucine, microcrystalline cellulose, shellac glaze and titanium dioxide
	72 mcg	calcium chloride dihydrate, gelatin, hypromellose, iron oxide black, iron oxide yellow, L-histidine, microcrystalline cellulose, polyvinyl alcohol, shellac glaze, talc and titanium dioxide

CONSTELLA contains linaclotide-coated beads in hard gelatin capsules. CONSTELLA is available as 72 mcg, 145 mcg or 290 mcg capsules for oral administration.

- 72 mcg Capsules: Each 72 mcg white to off-white, opaque, hard, gelatin capsule is imprinted with grey imprint “FL 72”. Available in bottles of 4 or 30 capsules.
- 145 mcg Capsules: Each 145 mcg white to off-white, opaque, hard, gelatin capsule is imprinted with a grey imprint “FL 145.” Available in bottles of 4 or 30 capsules.
- 290 mcg Capsules: Each 290 mcg white to off-white, opaque, hard, gelatin capsule is imprinted with a grey imprint “FL 290.” Available in bottles of 4 or 30 capsules.

## 7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

### Gastrointestinal

#### Diarrhea

Diarrhea was the most common adverse reaction of CONSTELLA-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar between IBS-C and CIC populations. The incidence of diarrhea was higher in linaclotide-treated patients than placebo-treated patients. See [8 ADVERSE REACTIONS](#). Severe diarrhea was reported in 2% of the 145 mcg and 290 mcg CONSTELLA-treated patients, and in <1% of 72 mcg CONSTELLA-treated CIC patients.

Instruct patients to stop CONSTELLA if severe diarrhea occurs and to contact their healthcare provider, who should consider dose suspension. See [8 ADVERSE REACTIONS](#).

## 7.1 Special Populations

### 7.1.1 Pregnant Women

There are no adequate and well-controlled studies with CONSTELLA in pregnant women. In animal developmental studies, adverse fetal effects were observed only with maternal toxicity and at doses of linaclotide much higher than the maximum recommended human dose. CONSTELLA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. See [Reproductive and Developmental Toxicology](#).

### 7.1.2 Breast-feeding

CONSTELLA is minimally absorbed following oral administration and neither linaclotide nor its active metabolite were detected in the milk of lactating women (see [10.3 Pharmacokinetics](#)). Therefore breastfeeding is not expected to result in exposure of the infant to CONSTELLA. The effects of linaclotide or its metabolite on milk production in lactating women have not been studied.

### 7.1.3 Pediatrics

CONSTELLA is contraindicated in children under 6 years of age and is not recommended for use in children between 6 and 18 years of age as the safety and efficacy of CONSTELLA in pediatric patients have not been established. Health Canada has not authorized an indication for pediatric use. As guanylate cyclase-C (GC-C) is known to be overexpressed at early ages, children may be particularly sensitive to the effects of CONSTELLA and may be more likely to develop diarrhea and its potentially serious consequences. See [2 CONTRAINDICATIONS, Special Populations and Conditions](#) and [Juvenile Toxicity](#).

### 7.1.4 Geriatrics

**Irritable Bowel Syndrome with Constipation:** Of 1,605 IBS-C patients in the placebo-controlled clinical studies of CONSTELLA, 85 (5%) were at least 65 years of age, while 20 (1%) were at least 75 years old. Clinical studies of CONSTELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

**Chronic Idiopathic Constipation:** Of 2,498 CIC patients in the placebo-controlled clinical studies of CONSTELLA, 273 (11%) were at least 65 years of age, while 56 (2%) were at least 75 years old. Clinical studies of CONSTELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

## 8 ADVERSE REACTIONS

### 8.1 Adverse Reaction Overview

The safety of CONSTELLA in irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) was evaluated in 5,505 patients who were exposed to linaclotide in the Phase 2 and 3 clinical studies. Total exposure of IBS-C patients to linaclotide was 2,253 patient-years and total exposure of CIC patients to linaclotide was 1,636 patient-years.

Oral doses from 72 mcg to 966 mcg once daily were evaluated. Approximately 2,570 patients were treated for 6 months or longer, 2,040 patients for 1 year or longer, and 1,220 patients for 18 months or



longer (not mutually exclusive). CONSTELLA was generally well-tolerated, with most adverse events being mild to moderate in intensity.

The most commonly observed adverse reaction in both the CONSTELLA-treated IBS-C and CIC patients in placebo-controlled studies (incidence  $\geq 5\%$  and at least twice the rate of placebo) was diarrhea.

In placebo-controlled trials in patients with IBS-C 9.4% of patients treated with 290 mcg of CONSTELLA and 2.9% of patients treated with placebo discontinued prematurely due to adverse reactions. In the CONSTELLA treatment group, the most common reasons for discontinuation due to adverse reactions were diarrhea (5.3%) and abdominal pain (1.2%). In comparison, less than 1% of patients in the placebo group withdrew due to diarrhea or abdominal pain.

In placebo-controlled trials in patients with CIC, 2.9% of patients treated with 72 mcg and 6.3% of patients treated with 145 mcg of CONSTELLA discontinued prematurely due to adverse reactions compared with 2.4% of patients treated with placebo. In the CONSTELLA treatment groups, the most common reasons for discontinuation due to adverse reactions were diarrhea (2.4% with 72 mcg and 3.9% with 145 mcg) and abdominal pain (0 with 72 mcg and 0.7% with 145 mcg). In comparison, 0.2% and 0.4% of patients in the placebo group withdrew due to diarrhea and abdominal pain respectively.

In placebo-controlled trials in patients with IBS-C, a total of 0.7% of patients treated with 290 mcg of CONSTELLA and 1.1% of patients treated with placebo experienced at least 1 serious adverse event. There were no serious adverse events of diarrhea. Of the 7 serious adverse events that were reported in the CONSTELLA patients, 2 (pericarditis and pericardial effusion in 1 patient) were possibly related to treatment. Overall, serious adverse events were low and there was no obvious pattern in the types of serious adverse events experienced in either the placebo or CONSTELLA group.

In placebo-controlled trials in patients with CIC, 0.7% of patients treated with 72 mcg and 1.0% of patients treated with 145 mcg of CONSTELLA experienced at least 1 on-therapy serious adverse event compared with 1.7% of patients treated with placebo. There were no serious adverse events of diarrhea. Of the 12 serious adverse events that were reported in the CONSTELLA patients, 3 (colitis, bronchitis and atrial fibrillation in 1 patient each) were possibly related to treatment. Overall, serious adverse events were low and there was no obvious pattern in the types of serious adverse events experienced in either the placebo or CONSTELLA group.

## **8.2 Clinical Trial Adverse Reactions**

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

### **Irritable Bowel Syndrome with Constipation (IBS-C)**

#### ***Common Adverse Reactions***

The data described below reflect exposure to CONSTELLA in the two double-blind, placebo-controlled clinical trials involving 1,605 adult patients with IBS-C. Patients were randomized to receive placebo or 290 mcg CONSTELLA once daily on an empty stomach, for up to 26 weeks. Demographic characteristics were comparable between the CONSTELLA treatment group and placebo (see [14 CLINICAL TRIALS](#)).

Table 2 provides the incidence of adverse reactions reported in  $\geq 1\%$  of CONSTELLA-treated IBS-C patients and at an incidence that was greater than in placebo-treated patients in the Phase 3 placebo-controlled trials.

**Table 2 - Adverse Reactions Occurring in  $\geq 1\%$  of CONSTELLA-Treated Patients and at an Incidence Greater than in Placebo-Treated Patients in Two Phase 3 Placebo-Controlled Trials in IBS-C**

System Organ Class Preferred Term	CONSTELLA 290 mcg /day n=807 (%)	Placebo n=798 (%)
<b>Gastrointestinal disorders</b>		
Diarrhea	19.8	3.0
Abdominal pain	5.1	3.3
Flatulence	4.3	1.9
Abdominal distension	2.2	1.1
Vomiting	1.7	1.3
Gastroesophageal reflux disease	1.2	0.9
<b>General disorders and administration site conditions</b>		
Fatigue	1.5	1.4
<b>Infectious disease</b>		
Gastroenteritis viral	2.6	1.4

### **Diarrhea**

Diarrhea was the most commonly reported adverse reaction of the CONSTELLA -treated patients in the pooled IBS-C Phase 3 placebo-controlled trials. In these trials, 19.8% of CONSTELLA-treated patients reported diarrhea compared to 3.0% of placebo-treated patients. Severe diarrhea was reported in 2.0% of the CONSTELLA-treated patients versus less than 1% of the placebo-treated patients, and 5.3% of the CONSTELLA-treated patients discontinued due to diarrhea versus less than 1% of placebo-treated patients. The majority of reported cases of diarrhea started within the first 2 weeks of CONSTELLA treatment. See [Gastrointestinal](#).

### **Chronic Idiopathic Constipation (CIC)**

#### **Common Adverse Reactions**

The data described below reflect exposure to CONSTELLA in the two double-blind, placebo-controlled clinical trials involving 1,275 adult patients with CIC. Patients were randomized to receive placebo, 145 mcg CONSTELLA or 290 mcg CONSTELLA once daily on an empty stomach, for at least 12 weeks. Of these patients, 430 patients received CONSTELLA at the recommended dose of 145 mcg once daily, while 422 patients were treated with 290 mcg CONSTELLA once daily. Demographic characteristics were comparable between both CONSTELLA treatment groups and placebo (see [14 CLINICAL TRIALS](#)).

Table 3 - Adverse Reactions Occurring in  $\geq 1\%$  of All CONSTELLA-Treated Patients and at an Incidence Greater than in Placebo-Treated Patients in the Two Phase 3 Placebo-Controlled Trials in CIC provides the incidence of adverse reactions reported in  $\geq 1\%$  of CONSTELLA-treated CIC

patients in the 145 mcg and 290 mcg CONSTELLA treatment groups and at an incidence that was greater than in placebo-treated patients in the Phase 3 placebo-controlled trials.

**Table 3 - Adverse Reactions Occurring in  $\geq 1\%$  of All CONSTELLA-Treated Patients and at an Incidence Greater than in Placebo-Treated Patients in the Two Phase 3 Placebo-Controlled Trials in CIC**

System Organ Class Preferred Term	CONSTELLA 145 mcg /day n=430 (%)	CONSTELLA 290 mcg /day n=422 (%)	CONSTELLA Both Doses n=852 (%)	Placebo n=423 (%)
<b>Gastrointestinal</b>				
Diarrhea	16.0	14.2	15.1	4.7
Flatulence	5.6	5.0	5.3	5.2
Abdominal pain	4.0	4.7	4.3	3.1
Nausea	3.5	4.3	3.9	3.5
Abdominal distension	3.5	3.6	3.5	2.4
Abdominal pain upper	3.0	1.2	2.1	1.7
Dyspepsia	1.9	0.7	1.3	0.7
<b>Infections and infestations</b>				
Gastroenteritis viral	1.9	0.5	1.2	0.5
<b>Nervous system disorders</b>				
Dizziness	0.9	1.4	1.2	0.5

The safety of a 72 mcg dose was evaluated in a placebo-controlled trial in which 1223 patients were randomized to CONSTELLA 72 mcg, 145 mg or placebo once daily for 12 weeks (Trial 5). Demographic characteristics were comparable between both CONSTELLA treatment groups and Placebo. See [14 CLINICAL TRIALS](#).

Table 4 provides the incidence of adverse reactions reported in  $\geq 1\%$  of CONSTELLA-treated

CIC patients in the 72 mcg or 145 mcg CONSTELLA treatment groups and at an incidence that was greater than in placebo-treated patients in Trial 5.

**Table 4 - Adverse Reactions Occurring in  $\geq 1\%$  of CONSTELLA-Treated Patients at Either Dose and at an Incidence Greater than in Placebo-Treated Patients in Trial 5**

<b>System Organ Class Preferred Term</b>	<b>CONSTELLA 72 mcg /day n=411 (%)</b>	<b>CONSTELLA 145 mcg /day n=411 (%)</b>	<b>Placebo n=401 (%)</b>
<b>Gastrointestinal</b>			
Diarrhea	19.2	22.1	7.0
Abdominal distension	2.2	1.2	0.5
Flatulence	1.5	0.7	1.2
<b>Infections and infestations</b>			
Upper Respiratory Tract	1.5	1.5	1.2
Sinusitis	1.0	1.9	0.2
Nasopharyngitis	0.5	1.5	0.5

### Diarrhea

Diarrhea was the most commonly reported adverse reaction of the CONSTELLA-treated patients in the pooled CIC Phase 3 placebo-controlled trials. Severe diarrhea was reported in less than 1% of the 72 mcg CONSTELLA-treated patients (Trial 5) and in 1.6% (Trials 3 and 4) and 2.4% (Trial 5) of 145 mcg CONSTELLA-treated patients versus less than 1% of the placebo-treated patients (Trials 3 and 4; Trial 5). The majority of reported cases of diarrhea started within the first 2 weeks of CONSTELLA treatment. See [Gastrointestinal](#).

## **8.3 Less Common Clinical Trial Adverse Reactions**

### **IBS-C**

Other adverse reactions that were reported in less than 1% of IBS-C patients are listed below by body system:

**Gastrointestinal disorders:** Abdominal discomfort, anal fissure, bowel movement irregularity, defecation urgency, eructation, fecal incontinence, feces discoloured, frequent bowel movements, gastrointestinal pain, gastrointestinal sounds abnormal, hemorrhoidal hemorrhage, rectal fissure, rectal tenesmus

**Infections and infestations:** Gastroenteritis

**Investigations:** Blood bicarbonate decreased

### **CIC**

Other adverse reactions that were reported in less than 1% of CIC patients are listed below by body system:

**Gastrointestinal disorders:** Abdominal discomfort, anal fissure, anorectal discomfort, defecation urgency, fecal incontinence, feces discoloured, frequent bowel movements, gastroesophageal reflux disease, gastrointestinal pain, gastrointestinal sounds abnormal, hemorrhoids, mucous stools, proctalgia, rectal spasm

**General disorders and administration site conditions:** Fatigue

**Investigations:** Blood magnesium decreased, blood potassium decreased, blood pressure decreased

**Metabolism and nutrition disorders:** Dehydration, hyponatremia

**Nervous system disorders:** Presyncope, syncope

**Renal and urinary disorders:** Azotemia

**Vascular disorders:** Orthostatic hypotension

#### **8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data**

No clinically significant changes in laboratory findings were identified during clinical trials or post-market.

#### **8.5 Post-Market Adverse Reactions**

At this time, no additional adverse reactions have been identified in post-market.

### **9 DRUG INTERACTIONS**

#### **9.2 Drug Interactions Overview**

Linaclotide and its active metabolite are not measurable in plasma following administration of the recommended clinical doses; hence, no systemic drug-drug interactions or drug interactions mediated by plasma protein binding of linaclotide or its metabolite are expected. See [10.3 Pharmacokinetics](#).

Linaclotide does not interact with the cytochrome P450 enzyme system based on the results of *in vitro* studies. In addition, linaclotide is neither a substrate nor an inhibitor of the efflux transporter P-glycoprotein (P-gp).

#### **9.3 Drug-Behavioural Interactions**

Drug-behavioural interactions have not been established.

#### **9.4 Drug-Drug Interactions**

No drug-drug interaction studies have been conducted with CONSTELLA.

#### **9.5 Drug-Food Interactions**

Taking CONSTELLA immediately after a high fat breakfast resulted in looser stools and a higher stool frequency compared with taking it in the fasted state, in healthy subjects; the effect in patients with IBS-C and CIC has not been established. In clinical trials, CONSTELLA was administered on an empty stomach, at least 30 minutes before breakfast. See [10.3 Pharmacokinetics](#).

#### **9.6 Drug-Herb Interactions**

Interactions with herbal products have not been established.

#### **9.7 Drug-Laboratory Test Interactions**

Interactions with laboratory tests have not been established.

## 10 CLINICAL PHARMACOLOGY

Irritable bowel syndrome (IBS) is a functional bowel disorder in which abdominal pain and discomfort are associated with altered defecation. The disorder has a spectrum ranging from mild to severe and is associated with deterioration in quality of life. The etiology and pathophysiology are poorly understood and appear to be multifactorial, resulting from a combination of visceral hypersensitivity, alteration in gastrointestinal (GI) motility, and psychosocial factors. Treatment of IBS is aimed at symptomatic relief of abdominal symptoms (i.e., abdominal pain, abdominal discomfort, and bloating), normalization of defecation, and improvement of quality of life.

Chronic idiopathic constipation (CIC) is a functional GI disorder. Patients with CIC report multiple bowel and abdominal symptoms including straining, gas, hard stools, abdominal discomfort, infrequent bowel movements, bloating, a sense of incomplete evacuation, and abdominal pain. Treatment of CIC is aimed at normalizing the frequency and consistency of bowel movements, as well as relieving the abdominal symptoms commonly associated with this condition.

### 10.1 Mechanism of Action

Linaclotide, a synthetic 14-amino acid peptide, is a potent and selective guanylate cyclase-C (GC-C) agonist with visceral analgesic and secretory activities. This first-in-class orally active peptide is structurally related to the guanylin peptide family, which is involved in the regulation of fluid homeostasis and bowel function of the GI tract. Both linaclotide and its active metabolite bind to GC-C and act locally on the luminal surface of the intestinal epithelium. Activation of GC-C results in an increase in both intracellular and extracellular concentrations of cyclic guanosine monophosphate (cGMP). Elevation in intracellular cGMP stimulates secretion of chloride and bicarbonate into the intestinal lumen, through activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit. Linaclotide has been shown to both accelerate GI transit and reduce intestinal pain. The linaclotide-induced reduction in visceral pain is thought to be mediated by increased extracellular cGMP, which was shown to decrease the activity of pain-sensing nerves.

### 10.2 Pharmacodynamics

Although the pharmacologic effects of CONSTELLA in humans have not been fully evaluated, CONSTELLA has been shown, in clinical studies, to accelerate colonic transit, soften stools, and increase stool frequency.

Orally administered linaclotide acts on the luminal surface of the intestine. The pharmacodynamics of orally administered linaclotide was evaluated in healthy subjects and patients through bowel symptom assessments of stool, severity of straining associated with bowel movements, stool frequency, and stool weight. Because the form of the feces largely depends on the time spent in the colon (i.e., slower transit results in harder stool form), stool consistency is a surrogate for GI transit. Single (29 mcg to 2897 mcg) and repeated once daily doses (29 mcg to 966 mcg) of linaclotide softened stools and decreased straining with bowel movements in healthy subjects relative to placebo, with more profound effects noted following doses  $\geq$  290 mcg.

Oral administration of linaclotide (97 mcg or 966 mcg) for five days to IBS-C patients, softened stools, increased stool frequency, improved ease of passage, and decreased time to first bowel movement, with a dose-dependent response for stool consistency. In addition to its effects on bowel movement parameters in these IBS-C patients, linaclotide was found to increase colonic transit using radiographic techniques.

## **Animal Pharmacology**

### **In vitro pharmacodynamics**

Several competitive binding studies were conducted using radiolabeled pSTa (*E. coli* heat-stable enterotoxin derived from a porcine source) to confirm the molecular target of linaclotide and characterize its binding to guanylate cyclase-C (GC-C). Linaclotide and its active primary metabolite, MM-419447, each bound with similar high affinities to human colon carcinoma T84 cells, which are known to express high levels of GC-C. The binding was found to be pH-independent. Linaclotide bound to rat intestinal epithelial cells and brush-border membranes with high affinity, providing further evidence that linaclotide binds to GC-C. A study using intestinal mucosal membranes from wild-type (WT) and GC-C knock-out (KO) mice showed high affinity binding of linaclotide to GC-C in intestinal mucosal membranes from WT mice, but not those from GC-C KO mice, confirming that the GC-C is the molecular target of linaclotide.

Upon binding to GC-C, both linaclotide and its active metabolite stimulate the production of cGMP intracellularly, in a concentration-dependent manner, with similar minimal effective concentrations in human T84 cells. In human colonic adenocarcinoma (Caco-2) cell monolayers, linaclotide increased intracellular cGMP and induced both basolateral (submucosal) and apical (luminal) cGMP efflux. This bidirectional cGMP efflux was inhibited by several known efflux transporter inhibitors, demonstrating that intracellular cGMP is actively transported out from intestinal epithelial cells.

### **In vivo pharmacodynamics**

The pharmacological activities of linaclotide and MM-419447 have been characterized in a number of studies in rodent models of intestinal secretion, GI transit, and visceral pain. Linaclotide and MM-419447 stimulated a significant, dose-dependent increase in intestinal secretion in suckling mice with equal potency at a minimal effective dose of 2.5 mcg/kg. In adult mice and rats, using a loop-ligation assay, linaclotide stimulated a significant increase in intestinal fluid secretion, accompanied by a significant increase in luminal cGMP secretion. The effect of linaclotide on intestinal fluid and cGMP secretion is GC-C dependent since the effect was only observed in WT mice, but not in GC-C KO mice.

In mice, linaclotide at oral doses of 25 mcg/kg (single dose) and 60 mcg/kg, QD (5-day repeat dosing) significantly induced GI transit in WT mice, but not in GC-C KO mice. In Sprague-Dawley rats, both linaclotide at 6.25 mcg/kg, p.o. and MM-419447 at 12.5 mcg/kg, p.o. produced a significant increase in GI transit.

In addition to its effect on intestinal secretion and GI transit, linaclotide significantly reduced visceral hypersensitivity. In a model of trinitrobenzene sulfonic acid (TNBS)-induced visceral hypersensitivity in WT mice, linaclotide (0.01 mcg/kg, p.o.) reduced visceral hyperalgesia but had no effect in GC-C KO mice. In models of both inflammation- and stress-induced (i.e., partial restraint, water avoidance) visceral hyperalgesia in rats, linaclotide produced antinociceptive effects, without affecting the colonic tone. However, a clear dose-response relationship was not observed.

### **Safety pharmacology**

Linaclotide tested at 10 and 100 µM concentrations exhibited negligible and not statistically significant inhibition (10 µM = 3.7% ± 2.0%; 100 µM = 0.9% ± 0.8%; vehicle = 0.7% ± 0.3%) of the human ether-a-go-go-related gene (hERG) channel current when tested *in vitro* in stably transfected human embryonic kidney (HEK) cells. In an *in vivo* safety pharmacology study, linaclotide did not produce any noticeable adverse respiratory or cardiovascular effects in dogs after administration of intravenous doses of up to 5 mg/kg.

### 10.3 Pharmacokinetics

**Absorption:** CONSTELLA is minimally absorbed with low systemic availability following oral administration. Concentrations of linaclotide and its active metabolite in plasma were below the limit of quantitation after oral doses of 145 mcg or 290 mcg were administered, regardless of participant gender, age, or race. Therefore, standard pharmacokinetic parameters such as area under the curve (AUC), maximum concentration ( $C_{\max}$ ) and half-life ( $t_{1/2}$ ) cannot be calculated.

**Distribution:** Given that linaclotide plasma concentrations following therapeutic oral doses are not measurable, linaclotide is expected to be minimally distributed to tissues.

**Metabolism:** Linaclotide is metabolized within the gastrointestinal tract to its principal, active metabolite by loss of the terminal tyrosine moiety. Both linaclotide and the metabolite are proteolytically degraded within the intestinal lumen to smaller peptides and naturally occurring amino acids.

**Elimination:** Active peptide recovery in the stool samples of fasted and fed subjects following the daily administration of 290 mcg of linaclotide for seven days averaged ~5 % (fasted) and ~3 % (fed) and virtually all as the active metabolite. These results ~~also~~ demonstrate that despite the early rapid metabolism and degradation of linaclotide and MM-419447 in the proximal small intestine, some active peptide is available to interact with GC-C throughout the entire intestinal tract, including the colon.

**Food Effect:** In a cross-over study, 18 healthy subjects were administered CONSTELLA 290 mcg for 7 days both in the non-fed and fed state. Neither linaclotide nor its active metabolite was detected in the plasma. Taking CONSTELLA immediately after the high fat breakfast resulted in looser stools and a higher stool frequency compared with taking it in the fasted state. In clinical trials, CONSTELLA was administered on an empty stomach, at least 30 minutes before breakfast.

No clinical studies assessing drug-drug interactions were conducted. Linaclotide has a low permeability coefficient in Caco-2 cells and is not a substrate, inhibitor, or inducer of cytochrome P450 enzymes. At clinically relevant concentrations, linaclotide is not a substrate for P-glycoprotein (P-gp) and does not inhibit common efflux and uptake transporters, including P-gp. The observed minimal systemic exposure to linaclotide and MM-419447 following oral administration of linaclotide, the extensive metabolism of both peptides within the GI tract, and the lack of interaction with common drug-transporting and drug-metabolizing enzymes have led to the conclusion that linaclotide is unlikely to interact with concomitantly administered medications.

#### Animal pharmacokinetics

Following oral dosing, linaclotide is minimally absorbed in all studied species, including mice, rats, and monkeys, with a low absolute oral bioavailability ( $\leq 0.2\%$ ).

While the predominant mechanism of clearance of orally administered linaclotide and its active primary metabolite is through proteolytic degradation in the lumen of the intestine, fecal recovery studies in rats have shown that a small amount of active peptide ( $\leq 1\%$ ), predominately in the form of the active metabolite, is excreted in the feces. These results also demonstrate that despite early rapid metabolism and degradation of linaclotide and MM-419447 in the proximal small intestine, some active peptide is available to interact with GC-C throughout the entire intestinal tract, including the colon.

Although very little active peptide is absorbed into systemic circulation after oral administration, when given intravenously in rats, both linaclotide and MM-419447 are rapidly cleared by at least two pathways. The kidney is a major clearance organ for systemically circulating linaclotide and



MM-419447, and studies have indicated the presence of additional, non-renal pathways of clearance, including biliary clearance.

### Special Populations and Conditions

- **Pediatrics:** Clinical studies to determine the impact of age on the clinical pharmacokinetics of linaclotide have not been conducted as linaclotide is rarely detectable in plasma. CONSTELLA is contraindicated in children under 6 years of age and is not recommended for use in children between 6 and 18 years of age as the safety and efficacy of CONSTELLA in pediatric patients have not been established (see [2 CONTRAINDICATIONS](#), [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#) and [Juvenile Toxicity](#))
- **Geriatrics:** Clinical studies to determine the impact of age on the pharmacokinetics of CONSTELLA have not been conducted (see [7.1.4 Geriatrics](#)) for information regarding patients aged 65 years and older.
- **Breast-feeding:** A pharmacokinetic study assessed the amount of linaclotide and its active metabolite in breast milk following multiple, once daily doses of oral linaclotide (72 µg, 145 µg, or 290 µg) in seven lactating women receiving the drug therapeutically. The concentrations of linaclotide and its metabolite in breast milk were below the limits of quantitation (LoQ) (<0.25 ng/mL and <1.00 ng/mL, respectively) in all samples during the dosing interval. Therefore breastfeeding is not expected to result in exposure of linaclotide or its metabolite to the breastfed child.

There is no information on the effects of linaclotide or its active metabolite on milk production (see [7.1.2 Breastfeeding](#)). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for CONSTELLA and any potential adverse effects on the breastfed infant from CONSTELLA or from the underlying maternal condition.

- **Sex:** Clinical studies to determine the impact of gender on the pharmacokinetics of CONSTELLA have not been conducted. Gender is not expected to affect the pharmacokinetics of CONSTELLA.
- **Hepatic Insufficiency:** CONSTELLA has not been specifically studied in patients who have hepatic impairment. Hepatic impairment is not expected to affect the metabolism or clearance of the parent drug or its metabolite because linaclotide has low systemic availability following oral administration and is metabolized within the gastrointestinal tract.
- **Renal Insufficiency:** CONSTELLA has not been specifically studied in patients who have renal impairment. Renal impairment is not expected to affect clearance of the parent drug or its metabolite because linaclotide has low systemic availability following oral administration and is metabolized within the gastrointestinal tract.

### 11 STORAGE, STABILITY AND DISPOSAL

Store at room temperature (15°C to 25°C).

Keep CONSTELLA in the original container. Do not subdivide or repackage. Protect from moisture. Do not remove desiccant from the container. Keep bottles tightly closed in a dry place.

### 12 SPECIAL HANDLING INSTRUCTIONS

There are no special handling instructions.



## 14 CLINICAL TRIALS

### 14.1 Clinical Trials by Indication

#### Irritable Bowel Syndrome with Constipation (IBS-C)

**Table 5 - Summary of Patient Demographics for Clinical Trials Supporting Efficacy of CONSTELLA in the Treatment of IBS-C (Intention-to-Treat [ITT] Population)**

Trial #	Trial Design/Duration	Oral Dosage	Study Subjects (N) [Female/Male (F/M)]	Mean Age (Range)	Mean Baseline Characteristics
1	12-week, randomized, multicenter, double-blind, placebo-controlled, Plus 4-week randomized withdrawal (RW) period	CONSTELLA 290 mcg, once daily	N=800 [F=724; M=76]	43.5 (18-84)	CSBMs/week: 0.2 (0.0-2.9)  Abdominal pain <sup>a</sup> (min, max): 5.6 (2.8-10)
2	26-week, randomized, multicenter, double-blind, placebo-controlled	CONSTELLA 290 mcg, once daily	N=804 [F=720; M=84]	44.3 (18-87)	CSBMs/week: 0.2 (0.0-2.9)  Abdominal pain <sup>a</sup> (min, max): 5.6 (2.9-10)
<sup>a</sup> Abdominal pain score based on 11-point numerical rating scale (NRS) (0=none, 10=very severe) CSBM=Complete Spontaneous Bowel Movement					

The efficacy of CONSTELLA for the treatment of IBS-C was established in two double-blind, placebo-controlled, randomized, multicenter trials in adult patients (Trials 1 and 2). A total of 800 patients in Trial 1 and 804 patients in Trial 2 received treatment with CONSTELLA 290 mcg or placebo once daily, and were evaluated for efficacy. A summary of trial designs and patient demographics is presented in Table 5 above. In the two pivotal trials, 77% of patients were White, 19% were Black, and 12% were Hispanic.

All patients met Rome II criteria for IBS and were required, during the 2-week baseline period, to meet the following criteria:

- a mean abdominal pain score of at least 3 on a 0-to10-point numeric rating scale,
- less than 3 complete spontaneous bowel movements (CSBMs) per week [a CSBM is a spontaneous bowel movement (SBM) that is associated with a sense of complete evacuation; a SBM is a bowel movement occurring in the absence of laxative use], and
- less than or equal to 5 SBMs per week.

The trial designs were identical through the first 12 weeks, and thereafter differed only in that Trial 1 included a 4-week randomized withdrawal (RW) period, and Trial 2 continued for 14 additional weeks (total of 26 weeks) of double-blind treatment. During the trials, patients were allowed to continue stable doses of bulk laxatives or stool softeners but were not allowed to take bismuth, prokinetic agents, or other drugs to treat IBS-C including laxatives (except for bisacodyl, the protocol-specified rescue medication).

## **Study Results**

Efficacy of CONSTELLA was assessed using overall responder analyses (primary endpoints) and change-from-baseline analyses (secondary endpoints). Results for endpoints were based on information provided daily by patients in electronic diaries, via an interactive voice response system.

### Primary Endpoints

The 4 primary efficacy responder endpoints were based on a patient being a weekly responder for either at least 9 out of the first 12 weeks of treatment or at least 6 out of the first 12 weeks of treatment. For the 9 out of 12 weeks combined primary responder endpoint, a patient had to have at least a 30% reduction from baseline in mean abdominal pain, at least 3 CSBMs and an increase of at least 1 CSBM from baseline, all in the same week, for at least 9 out of the first 12 weeks of treatment. Each of the 2 components of the 9 out of 12 weeks combined responder endpoint, abdominal pain and CSBMs, was also a primary endpoint.

For the 6 out of 12 weeks combined primary responder endpoint, a patient had to have at least a 30% reduction from baseline in mean abdominal pain and an increase of at least 1 CSBM from baseline, all in the same week, for at least 6 out of the first 12 weeks of treatment. To be considered a responder for this analysis, patients did not have to have at least 3 CSBMs per week.

In the two pivotal trials (Trials 1 and 2) CONSTELLA demonstrated statistically superior benefits, for the primary endpoint, compared to placebo in the treatment of IBS-C. In both trials, the proportion of patients who were responders to CONSTELLA 290 mcg was statistically significantly higher than with placebo. The primary efficacy results are shown in Table 6 below.

**Table 6 - Primary Efficacy of CONSTELLA in IBS-C (ITT Population)**

Primary Responder Endpoints	Trial 1			Trial 2		
	CONSTELLA 290 mcg (N=405)	Placebo (N=395)	Treatment Difference [95% CI]	CONSTELLA 290 mcg (N=401)	Placebo (N=403)	Treatment Difference [95% CI]
9/12 Week Combined Responder (Abdominal Pain and CSBM Responder)	12.1% <sup>b</sup>	5.1%	7.0% [3.2%, 10.9%]	12.7 <sup>c</sup>	3.0%	9.7% [6.1%, 13.4%]
CSBM Responder (≥ 3 CSBMs and Increase ≥ 1 CSBM from Baseline)	19.5 <sup>c</sup>	6.3%	13.2% [8.6%, 17.7%]	18.0 <sup>c</sup>	5.0%	13.0% [8.7%, 17.3%]
Abdominal Pain Responder (≥ 30% Reduction)	34.3% <sup>a</sup>	27.1%	7.2% [0.9%, 13.6%]	38.9% <sup>c</sup>	19.6%	19.3% [13.2%, 25.4%]
6/12 Week Combined Responder (Abdominal Pain and CSBM Responder)	33.6% <sup>c</sup>	21.0%	12.6% [6.5%, 18.7%]	33.7% <sup>c</sup>	13.9%	19.8% [14.0%, 25.5%]
<sup>a</sup> p≤0.05, <sup>b</sup> p<0.001, <sup>c</sup> p<0.0001 Note: Analyses based on first 12 weeks of treatment for both Trials 1 and 2 CI = Confidence Interval, CSBM=Complete Spontaneous Bowel Movement						

**Secondary Endpoints**

The secondary efficacy endpoints consisted of both responder and change from baseline assessments. The responder endpoints were based on a patient being a CSBM weekly responder or an abdominal pain responder for at least 6 out of the first 12 weeks of treatment. For the 6 out of 12 weeks CSBM responder endpoint, a patient had to have an increase of at least 1 CSBM from baseline for at least 6 out of the first 12 weeks of treatment. For the abdominal pain responder, a patient had to have at least a 30% reduction from baseline in mean abdominal pain.

The change from baseline secondary endpoints were the change from baseline in 12-week CSBM and SBM frequency rate, stool consistency, severity of straining, abdominal pain at its worst, abdominal discomfort, bloating and percent of abdominal pain-free days.

In Trial 1 and 2, for the 6/12 week CSBM and abdominal pain endpoints, statistically significantly more patients receiving CONSTELLA 290 mcg were responders versus placebo (Table 7).

**Table 7 - Secondary Efficacy of CONSTELLA in IBS-C (6/12 Week Responder Endpoints, ITT Population)**

Secondary Responder Endpoints	Trial 1			Trial 2		
	CONSTELLA 290 mcg (N=405)	Placebo (N=395)	Treatment Difference (%) [95% CI]	CONSTELLA 290 mcg (N=401)	Placebo (N=403)	Treatment Difference (%) [95% CI]
<b>CSBM Responder (Increase <math>\geq</math> 1 CSBM from Baseline)</b>	48.6% <sup>c</sup>	29.6%	19.0% [12.4%, 25.7%]	47.6% <sup>c</sup>	22.6%	25.1% [18.7%, 31.4%]
<b>Abdominal Pain Responder (<math>\geq</math> 30% Abdominal Pain Reduction)</b>	50.1% <sup>b</sup>	37.5%	12.7% [5.8%, 19.5%]	48.9% <sup>c</sup>	34.5%	14.4% [7.6%, 21.1%]
<sup>a</sup> p $\leq$ 0.05, <sup>b</sup> p $<$ 0.001, <sup>c</sup> p $<$ 0.0001 Note: Analyses based on first 12 weeks of treatment for Both Trials 1 and 2 CI=Confidence Interval, CSBM=Complete Spontaneous Bowel Movement						

For change-from-baseline endpoints, patients who received CONSTELLA 290 mcg across the 2 trials demonstrated statistically significantly greater improvements compared with patients receiving placebo in both abdominal symptoms (pain, discomfort and bloating) and bowel symptoms (straining, stool frequency and consistency) (Table 8). In a pooled analysis of Trials 1 and 2, 67% of CONSTELLA - treated patients had an SBM within 24 hours of taking their first dose versus 42% of placebo patients (p < 0.0001).

**Table 8 - Secondary Efficacy of CONSTELLA in IBS-C (Mean Change from Baseline, ITT Population)**

12-week Parameter	Trial 1			Trial 2		
	CONSTELLA 290 mcg (N=405)	Placebo (N=395)	LSMD [95% CI]	CONSTELLA 290 mcg (N=401)	Placebo (N=403)	LSMD [95% CI]
CSBMs/Week	2.3 <sup>c</sup>	0.7	1.6 (1.2, 1.9)	2.2 <sup>c</sup>	0.7	1.5 (1.2, 1.9)
SBMs/Week	3.9 <sup>c</sup>	1.1	2.8 (2.3, 3.2)	4.0 <sup>c</sup>	1.3	2.7 (2.3, 3.2)
Stool Consistency (BSFS Score)	2.1 <sup>c</sup>	0.7	1.4 (1.3, 1.6)	1.9 <sup>c</sup>	0.6	1.3 (1.1, 1.5)
Straining (5-point Ordinal scale)	-1.3% <sup>c</sup>	-0.7	-0.7 (-0.8, -0.5)	-1.2 <sup>c</sup>	-0.7	-0.6 (-0.7, -0.5)
Abdominal Pain at its Worst (11-point NRS)	-1.9 <sup>c</sup>	-1.1	-0.7 (-1.0, -0.5)	-1.9 <sup>c</sup>	-1.1	-0.8 (-1.0, -0.5)
Abdominal Discomfort (11- point NRS)	-2.0 <sup>c</sup>	-1.2	-0.7 (-1.0, -0.5)	-1.9 <sup>c</sup>	-1.1	-0.8 (-1.1, -0.6)
Bloating (11-point NRS)	-1.9 <sup>c</sup>	-1.1	-0.8 (-1.1, -0.6)	-1.9 <sup>c</sup>	-1.0	-0.9 (-1.1, -0.6)
Percent of Abdominal Pain- free Days	9.8 <sup>a</sup>	5.3	4.5 (1.9, 7.2)	10.5 <sup>b</sup>	4.8	5.7 (2.9, 8.5)
<sup>a</sup> p≤0.05, <sup>b</sup> p<0.001, <sup>c</sup> p<0.0001 Note: Analyses based on first 12 weeks of treatment for both Trials 1 and 2 BSFS=Bristol Stool Form Scale, CI=Confidence Interval, CSBM=Complete Spontaneous Bowel Movement, LSMD=Least Squares Mean Difference, SBM=Spontaneous Bowel Movement, NRS=Numerical Rating Scale						


In each trial, improvement from baseline in abdominal pain and CSBM frequency was seen over the first 12-weeks of the treatment periods. For change from baseline in the 11-point abdominal pain scale, CONSTELLA 290 mcg began to separate from placebo in the first week. Maximum effects were seen at Weeks 6 - 9 and were maintained until the end of the study. The mean treatment difference from placebo at Week 12 was a decrease in pain score of approximately 1.0 point in both trials (using an 11-point scale).

The maximum effect on CSBM frequency occurred within the first week. For the change from baseline in CSBM frequency at Week 12, the difference between placebo and CONSTELLA was approximately 1.5 CSBMs per week in both trials.

The proportions of patients who met response criteria of increasing levels of symptom improvement compared to baseline over 12 weeks of treatment were analyzed for both abdominal pain and CSBMs.

At each level, a statistically significantly greater proportion of patients treated with CONSTELLA 290 mcg met the response criterion compared to placebo patients (Figure 1).

**Figure 1 - Percentage of Patients with Specified Improvements in (a) Abdominal Pain and (b) CSBMs over the First 12 Weeks of Treatment in IBS-C (Trials 1 & 2, Pooled ITT Population)**




CSBM=Complete Spontaneous Bowel Movement

Figure 2 presents results for improvement in abdominal pain (% change from baseline) for each of the 26 weeks of treatment in Trial 2. CONSTELLA 290 mcg demonstrated a statistically significant separation from placebo that was present at the first week and sustained across the 26 weeks of the treatment period ( $p < 0.001$  at all time-points during the treatment period). Similar results for improvement in CSBM frequency were demonstrated throughout the 26-week treatment period. Maximum effect on CSBM frequency occurred by Week 1, but the effect on abdominal pain continued to increase over the first 6 to 8 weeks.



**Figure 2 - Trial 2 - Mean Percentage Improvement in Abdominal Pain by Week over 26 Weeks in IBS-C**



CI=Confidence Interval

During the 4-week randomized withdrawal period in Trial 1, patients who received CONSTELLA during the 12-week treatment period were re-randomized to receive placebo or continue treatment on CONSTELLA 290 mcg. In CONSTELLA-treated patients re-randomized to placebo, CSBM frequency and abdominal-pain severity returned toward baseline within 1 week with no evidence of rebound worsening compared to baseline. Patients who continued on CONSTELLA maintained their response to therapy over the additional 4 weeks. Patients on placebo who were allocated to CONSTELLA had an increase in CSBM frequency and abdominal pain levels that were similar to the levels observed in patients taking CONSTELLA during the treatment period.

#### Quality of Life Assessment

The Irritable Bowel Syndrome-Quality of Life (IBS-QOL) instrument was utilized in the Phase 3 pivotal trials to assess the impact of IBS on a patient's quality of life. The IBS-QOL evaluated 8 dimensions: dysphoria, interference with activity, body image, health worry, food avoidance, social reaction, sexual, and relationships on a 0 to 100 point scale. A pooled analysis of the IBS-QOL data at Week 12 demonstrated that a higher proportion of patients receiving CONSTELLA 290 mcg were responders versus placebo for the overall score and the 8 subscale scores (all  $p < 0.05$ ). Table 9 provides an overview of the IBS-QOL responder data from Trials 1 and 2.

**Table 9 - Quality of Life Results for CONSTELLA in IBS-C (Responder Analyses, Pooled ITT Population)**

IBS-QOL Parameter	CONSTELLA 290 mcg N=805	Placebo N=797	CONSTELLA 290 mcg N=805	Placebo N=797
	% of Patients with ≥10 point improvement		% of patients with ≥14 point improvement	
<b>IBS-QOL Overall Score</b>	64.3% <sup>d</sup>	52. 5%	53.8% <sup>d</sup>	39.0%
<b>Dysphoria</b>	62.0% <sup>b</sup>	53.6%	56.2% <sup>d</sup>	45.7%
<b>Body Image</b>	71. 7% <sup>d</sup>	59.5%	62.1% <sup>d</sup>	43.2%
<b>Health Worry</b>	67.6% <sup>d</sup>	56.1%	67.6% <sup>d</sup>	56.1%
<b>Food Avoidance</b>	57.4% <sup>d</sup>	46.6%	57.4% <sup>d</sup>	46.6%
<b>Social Reaction</b>	52.5% <sup>b</sup>	44. 5%	42.4% <sup>c</sup>	32.9%
<b>Sexual</b>	54.2% <sup>c</sup>	44.4%	37.9% <sup>d</sup>	26.9%
<b>Relationships</b>	41.6% <sup>b</sup>	34.7%	41.6% <sup>b</sup>	34.7%
<b>Interference with Activity</b>	54.7% <sup>a</sup>	48.5%	47.5% <sup>b</sup>	39.0%
<sup>a</sup> p<0.05, <sup>b</sup> p <0.01, <sup>c</sup> p <0.001, <sup>d</sup> p<0.0001(vs. placebo, CMH test) IBS-QOL=Irritable Bowel Syndrome-Quality of Life				

## Chronic Idiopathic Constipation (CIC)

**Table 10 - Summary of Patient Demographics for Clinical Trials Supporting Efficacy of CONSTELLA in the Treatment of CIC (ITT Population)**

<b>Trial #</b>	<b>Trial Design/Duration</b>	<b>Oral Dosage</b>	<b>Study Subjects (N) [Female/Male (F/M)]</b>	<b>Mean Age (Range)</b>	<b>Mean Baseline Characteristics</b>
3	12-week, randomized, multicenter, double-blind, placebo-controlled, parallel-group Plus 4-week randomized withdrawal (RW) period	CONSTELLA 145 mcg or 290 mcg once daily	N=642 [F=561; M=81]	48.0 (18-85)	CSBMs/week: 0.3 (0.0-2.9)
4	12-week, randomized, multicenter, double-blind, placebo-controlled, parallel-group	CONSTELLA 145 mcg or 290 mcg once daily	N=630 [F=570; M=60]	47.6 (20-83)	CSBMs/week: 0.3 (0.0-2.4)
5	12-week, randomized, multicenter, double-blind, placebo-controlled, parallel-group	CONSTELLA 72 mcg or 145 mcg once daily	N = 1223 [F = 942; M = 281]	46.0 (18 – 90)	CSBMs/week 0.2 (0.0 – 2.9)

CSBM=Complete Spontaneous Bowel Movement

The efficacy of CONSTELLA for the treatment of CIC was established in two double-blind, placebo-controlled, randomized, multicenter trials in adult patients (Trials 3 and 4). A total of 642 patients in Trial 3 and 630 patients in Trial 4 received treatment with the recommended 145 mcg dose of CONSTELLA, the 290 mcg dose of CONSTELLA, or placebo once daily, and were evaluated for efficacy. A summary of trial designs and patient demographics is presented in Table 9 below. In the two pivotal trials, 76% of patients were White, 22% were Black, and 10% were Hispanic.

The efficacy of the 72 mcg dose (Trial 5) was established by using a 12-week CSBM Overall Responder endpoint that was the same as in Trials 3 and 4.

All patients met modified Rome II criteria (Trials 3 and 4) or Rome III criteria (Trial 5) for functional constipation. Modified Rome II criteria were less than 3 spontaneous bowel movements (SBMs) per week and 1 of the following symptoms for at least 12 weeks, which need not be consecutive, in the preceding 12 months (Rome II) or with onset at least 6 months before diagnosis (Rome III):

- Straining during greater than 25% of bowel movements
- Lumpy or hard stools during greater than 25% of bowel movements
- Sensation of incomplete evacuation during greater than 25% of bowel movements

Patients were also required to have less than 3 complete spontaneous bowel movements (CSBMs) per week and less than or equal to 6 SBMs per week during a 2-week baseline period. Patients were excluded if they met criteria for IBS-C or had fecal impaction that required emergency room treatment.

The trial designs were identical through the first 12 weeks. Trial 3 also included an additional 4-week randomized withdrawal (RW) period. During the trials, patients were allowed to continue stable doses of bulk laxatives or stool softeners but were not allowed to take bismuth, prokinetic agents, or other drugs to treat chronic constipation including laxatives (except for bisacodyl, the protocol-specified rescue medication).

## **Study Results**

### **Trials 3 and 4**

Efficacy of CONSTELLA was assessed using overall responder analysis (primary endpoint) and change-from-baseline analyses (secondary endpoints). Results for endpoints were based on information provided daily by patients in electronic diaries, via an interactive voice response system.

Both doses of CONSTELLA were statistically superior to placebo for the primary and secondary endpoints in each pivotal trial, with no incremental benefit of the 290 mcg dose over the 145 mcg dose. Therefore, the 145 mcg dose is the recommended dose.

### **Primary Endpoint**

The primary efficacy endpoint was the proportion (%) of patients who had at least 3 CSBMs and an increase of at least 1 CSBM from baseline in a given week for at least 9 weeks out of the 12-week treatment period.

In the two pivotal trials (Trials 3 and 4), CONSTELLA demonstrated statistically superior benefits, for the primary endpoint, compared to placebo in the treatment of CIC. In both trials, the proportion of patients who were CSBM responders was statistically significantly greater with CONSTELLA than with placebo. Results are summarized in Table 11 and Table 12.

**Table 11 - Trial 3 - Primary Efficacy of CONSTELLA in CIC (ITT Population)**

	Trial 3				
	Placebo (N=209)	CONSTELLA 145 mcg (N=217)	Treatment Difference [95% CI]	CONSTELLA 290 mcg (N=216)	Treatment Difference [95% CI]
<b>CSBM Responder (≥ 3 CSBMs and Increase ≥ 1 CSBM from Baseline)</b>	3.3%	21.2% <sup>a</sup>	17.8% [11.9%, 23.8%]	19.4% <sup>a</sup>	16.1% [10.3%, 21.9%]
<sup>a</sup> p<0.0001 CI=Confidence Interval, CSBM=Complete Spontaneous Bowel Movement					

**Table 12 - Trial 4 - Primary Efficacy of CONSTELLA in CIC (ITT Population)**

	Trial 4				
	Placebo (N=215)	CONSTELLA 145 mcg (N=213)	Treatment Difference [95% CI]	CONSTELLA 290 mcg (N=202)	Treatment Difference [95% CI]
<b>CSBM Responder<sup>a,b</sup> (≥ 3 CSBMs and Increase ≥ 1 CSBM from Baseline)</b>	6.0%	16.0% <sup>a</sup>	9.9% [4.1%, 15.8%]	21.3% <sup>b</sup>	15.2% [8.8%, 21.7%]
<sup>a</sup> p≤0.05, <sup>b</sup> p<0.0001 CI=Confidence Interval, CSBM=Complete Spontaneous Bowel Movement					

**Secondary Endpoints**

The secondary efficacy endpoints were the change from baseline in 12-week CSBM and SBM frequency, stool consistency, severity of straining, abdominal discomfort, bloating, and constipation severity.

Patients who received CONSTELLA across the 2 trials demonstrated statistically significantly greater improvements compared with patients receiving placebo for all secondary endpoints, including change from baseline in 12 week CSBM and SBM frequency, stool consistency (as measured by the Bristol Stool Form Scale (BSFS)), severity of straining, abdominal discomfort, bloating and constipation severity (Table 13 and

Table 14).

CSBM frequency reached maximum level during Week 1 and was also demonstrated over the remainder of the 12-week treatment period in Trial 3 and Trial 4. For the mean change from baseline in CSBM frequency at Week 12, the difference between placebo and CONSTELLA was approximately 1.5 CSBMs.

**Table 13 - Trial 3 - Secondary Efficacy of CONSTELLA in CIC (Mean Change from Baseline, ITT Population)**


<b>12-Week Parameter</b>	<b>Placebo (N=209)</b>	<b>CONSTELLA 145 mcg (N=217)</b>	<b>LSMD (95% CI)</b>	<b>CONSTELLA 290 mcg (N=216)</b>	<b>LSMD (95% CI)</b>
<b>CSBMs/week</b>	0.5	1.9 <sup>c</sup>	1.5 (1.0, 1.9)	2.0 <sup>c</sup>	1.6 (1.2, 2.0)
<b>SBMs/week</b>	1.1	3.0 <sup>c</sup>	2.0 (1.4, 2.5)	3.0 <sup>c</sup>	1.9 (1.4, 2.5)
<b>Stool Consistency*</b>	0.6	1.9 <sup>c</sup>	1.3 (1.1, 1.5)	1.8 <sup>c</sup>	1.3 (1.0, 1.5)
<b>Severity of Straining**</b>	-0.5	-1.1 <sup>c</sup>	-0.6 (-0.7, -0.5)	-1.2 <sup>c</sup>	-0.6 (-0.8, -0.5)
<b>Abdominal Discomfort**</b>	-0.3	-0.5 <sup>b</sup>	-0.2 (-0.3, -0.1)	-0.4 <sup>a</sup>	-0.1 (-0.2, 0.0)
<b>Bloating**</b>	-0.2	-0.5 <sup>c</sup>	-0.2 (-0.3, -0.1)	-0.4 <sup>a</sup>	-0.2 (-0.3, -0.1)
<b>Constipation Severity**</b>	-0.3	-0.9 <sup>c</sup>	-0.6 (-0.8, -0.5)	-0.8 <sup>c</sup>	-0.5 (-0.7, -0.4)
<sup>a</sup> p≤0.05, <sup>b</sup> p<0.001, <sup>c</sup> p<0.0001 *BSFS Score, **5-point Ordinal Scale BSFS=Bristol Stool Form Scale, CI=Confidence Interval, CSBM=Complete Spontaneous Bowel Movement, LSMD=Least Squares Mean Difference, SBM=Spontaneous Bowel Movement					

**Table 14 - Trial 4 - Secondary Efficacy of CONSTELLA in CIC (Mean Change from Baseline, ITT Population)**

<b>12-Week Parameter</b>	<b>Placebo (N=215)</b>	<b>CONSTELLA 145 mcg (N=213)</b>	<b>LSMD (95% CI)</b>	<b>CONSTELLA 290 mcg (N=202)</b>	<b>LSMD (95% CI)</b>
<b>CSBMs/week</b>	0.6	2.0 <sup>b</sup>	1.4 (0.9, 1.9)	2.7 <sup>b</sup>	2.0 (1.5, 2.6)
<b>SBMs/week</b>	1.1	3.4 <sup>b</sup>	2.3 (1.7, 3.0)	3.7 <sup>b</sup>	2.6 (1.9, 3.2)
<b>Stool Consistency*</b>	0.6	1.8 <sup>b</sup>	1.3 (1.0, 1.5)	2.0 <sup>b</sup>	1.4 (1.2, 1.7)
<b>Severity of Straining**</b>	-0.6	-1.1 <sup>b</sup>	-0.6 (-0.7, -0.4)	-1.2 <sup>b</sup>	-0.7 (-0.8, -0.5)
<b>Abdominal Discomfort**</b>	-0.3	-0.5 <sup>a</sup>	-0.2 (-0.3, -0.1)	-0.5 <sup>b</sup>	-0.2 (-0.3, -0.1)
<b>Bloating**</b>	-0.2	-0.4 <sup>a</sup>	-0.2 (-0.3, -0.1)	-0.5 <sup>b</sup>	-0.3 (-0.4, -0.1)
<b>Constipation Severity**</b>	-0.3	-0.9 <sup>b</sup>	-0.6 (-0.8, -0.5)	-1.0 <sup>b</sup>	-0.6 (-0.8, -0.5)
<sup>a</sup> p<0.001, <sup>b</sup> p<0.0001 *BSFS Score, **5-point Ordinal Scale BSFS=Bristol Stool Form Scale, CI=Confidence Interval, CSBM=Complete Spontaneous Bowel Movement, LSMD=Least Squares Mean Difference, SBM=Spontaneous Bowel Movement					

The proportions of patients who met response criteria of increasing levels of stool frequency compared to baseline (i.e., increases of >0, ≥1, ≥2, ≥3, ≥4, ≥5, and ≥6 CSBMs per week) over 12 weeks of treatment were analyzed. At each level, a statistically significantly greater proportion of patients treated with either dose of CONSTELLA met the response criterion compared with placebo patients (Figure 3).

**Figure 3 - Percentage of CIC Patients with Incremental Increases in CSBM Frequency (Trials 3 & 4, Pooled ITT Population)**



<sup>a</sup> p-value ≤0.0001 vs. Placebo


p≤0.0001 for all comparisons of linaclotide vs placebo  
CSBM=Complete Spontaneous Bowel Movement

For CSBM and SBM frequency, each dose of CONSTELLA demonstrated a statistically significant separation from placebo that was present at the first week and sustained across the 12 weeks of the treatment period (p < 0.001 for each dose vs. placebo at all time-points) for both trials.

During the 4-week randomized withdrawal period in Trial 3, patients who received CONSTELLA during the 12-week treatment period were re-randomized to receive placebo or continue treatment on the same dose of CONSTELLA taken during the treatment period. In CONSTELLA-treated patients re-randomized to placebo, CSBM and SBM frequency returned toward baseline within 1 week with no evidence of rebound worsening compared to baseline. Patients who continued on CONSTELLA maintained their response to therapy over the additional 4 weeks. Patients on placebo who were allocated to CONSTELLA had an increase in CSBM and SBM frequency similar to the levels observed in patients taking CONSTELLA during the treatment period (Figure 4).



**Figure 4 - Trial 3 - Mean (a) CSBM and (b) SBM Frequency by Week Over the 12-week Treatment Period and 4-week Randomized Withdrawal Period**



CSBM=Complete Spontaneous Bowel Movement, SBM=Spontaneous Bowel Movement

### Quality of Life Assessment

The Patient Assessment of Constipation – Quality of Life (PAC-QOL) instrument was utilized in the Phase 3 pivotal trials to assess the impact of constipation on a patient's quality of life. The PAC-QOL evaluated 4 dimensions: physical discomfort, psychosocial discomfort, worries/concerns, and satisfaction on a 0 to 4 point scale. A pooled analysis of the PAC-QOL data at Week 12 demonstrated that a higher proportion of patients receiving CONSTELLA 145 mcg or CONSTELLA 290 mcg were responders versus placebo for the overall score and the 4 subscale scores (all  $p < 0.05$ ). Table 15 provides an overview of the pooled PAC-QOL responder data from Trials 3 and 4.

**Table 15 - Quality of Life Results for CONSTELLA in CIC (Responder Analyses, Pooled ITT Population)**

PAC-QOL Parameter	CONSTELLA 145 mcg N=430	CONSTELLA 290 mcg N=418	Placebo N=423
	% of Patients with $\geq 1$ point improvement		
<b>PAC-QOL Overall Score</b>	43.6% <sup>b</sup>	41.0% <sup>b</sup>	23.4% <sup>b</sup>
<b>Satisfaction</b>	53.8% <sup>b</sup>	52.3% <sup>b</sup>	28.3% <sup>b</sup>
<b>Physical Discomfort</b>	55.4% <sup>b</sup>	54.6% <sup>b</sup>	30.8% <sup>b</sup>
<b>Worries/Concerns</b>	48.1% <sup>b</sup>	45.1% <sup>b</sup>	26.7% <sup>b</sup>
<b>Psychosocial Discomfort</b>	24.7% <sup>a</sup>	29.1% <sup>b</sup>	18.6% <sup>b</sup>

<sup>a</sup>  $p \leq 0.05$ , <sup>b</sup>  $p < 0.0001$  (vs. placebo, CMH test)  
PAC-QOL=Patient Assessment of Constipation-Quality of Life

### 72 mcg Trial (Trial 5)

The efficacy of the 72 mcg dose was established by using a 12-week CSBM Overall Responder endpoint that was the same as in Trials 3 and 4. In addition, to assess whether response was sustained over time,

a separate analysis (CSBM Sustained Responder) was performed, where responders were both a 12-week Overall Responder and a CSBM weekly responder for at least 3 of the last 4 weeks of the treatment period.

The response rates for the CSBM Overall Responder endpoint were 13.4% for CONSTELLA 72 mcg, 12.4% for CONSTELLA 145 mcg and 4.7% for placebo. Results for the 12-week CSBM Sustained Responder were 12.4% for CONSTELLA 72 mcg, 11.2% for CONSTELLA 145 mcg and 4.7% for placebo.

## **15 MICROBIOLOGY**

Not applicable

## **16 NON-CLINICAL TOXICOLOGY**

### **General Toxicology:**

#### **Single-dose Toxicity**

In rats, there was no detectable systemic exposure to linaclotide at single oral dose levels of up to 5.0 mg/kg (lower limit of quantitation [LLOQ] was 3 ng/mL). There were no linaclotide-related effects observed on survival, body weight, food consumption, clinical observations, or macroscopic evaluations. The no-observed-adverse-effect level (NOAEL) was determined to be  $\geq 5.0$  mg/kg in rats (both sexes) given linaclotide as a single oral dose.

Cynomolgus monkeys were administered a single oral dose of linaclotide at dose levels of 0.5, 1.5, 3.0, or 5.0 mg/kg. Monkeys receiving a single oral dose  $\geq 1.5$  mg/kg exhibited changes in stool consistency (non-formed and/or liquid feces), qualitatively reduced food consumption, and/or abdominal distention. There were no significant changes in individual body weight data for these animals. A monkey dosed orally for five consecutive days at 1.5 mg/kg/day exhibited non-formed and liquid feces over the course of the dosing period, with mild abdominal distention occurring on the fourth dosing day. These results demonstrated that linaclotide was well tolerated by Cynomolgus monkeys following a single oral dose at dose levels up to 5.0 mg/kg. Clinical signs related to the exaggerated pharmacological effects of linaclotide on stool consistency were observed at oral doses of  $\geq 1.5$  mg/kg/day.

#### **Repeat-dose Toxicity**

Repeated-dose studies of orally administered linaclotide have been conducted in mice, rats and monkeys. In Good Laboratory Practice (GLP) two-week repeated-dose oral toxicity studies in rats and monkeys, the administration of linaclotide at dose levels of 20 mg/kg/day in rats and 5 mg/kg/day in monkeys was associated with no noteworthy findings in rats and reversible changes in stool consistency in monkeys, respectively. In a GLP 7-day repeated-dose intravenous toxicity study in monkeys, the administration of linaclotide at a dose level of 15 mg/kg/day was associated with stool consistency changes.

In GLP repeated-dose oral toxicity studies in rats and monkeys, linaclotide did not produce findings considered to be adverse when administered for up to 13 weeks at doses up to 100 mg/kg/day in rats and up to 5 mg/kg/day in monkeys. Reversible changes in stool consistency were observed in monkeys and are the exaggerated pharmacological effect of linaclotide. During a GLP 13-week repeated-dose oral toxicity study in mice, mortality related to linaclotide administration was observed at dose levels  $\geq$

100 mg/kg/day. Linaclotide-related microscopic changes were noted in the lymphoid system (spleen and thymus), GI tract (stomach, cecum), kidney, and heart at doses  $\geq$  100 mg/kg/day in both males and females. The NOAEL for linaclotide in mice was 20 mg/kg/day administered orally once daily for 13 weeks.

Based upon the increased sensitivity of mice to linaclotide administration, mice were chosen as the species for the GLP 26-week repeated-dose oral toxicity study in rodents. In the 26-week toxicity study, mortality was observed early in the study in the high dose (100/80 mg/kg/day) group. However, no linaclotide-related clinical pathology changes, gross or microscopic findings were noted at any dose level in either sex. Based on the mortality observed, the NOAEL was 20 mg/kg/day in mice administered linaclotide orally for 26 weeks.

In the GLP 39-week study in monkeys, changes in stool consistency (watery feces) were present at all dose levels evaluated in both sexes and were consistent with the exaggerated pharmacological effects of linaclotide. Repeated daily oral dosing for up to 39 weeks did not result in any apparent decrease in the pharmacological effects of linaclotide on stool consistency during the dosing interval and the effects on stool consistency were reversible upon discontinuation of dosing. Two monkeys (one male at the mid dose [10 mg/kg/day] and one female at the high dose [50 mg/kg/day]) were euthanized moribund due to severe watery feces (e.g., diarrhea) and associated progressive dehydration. Mortality in these monkeys was considered to be related to exaggerated pharmacology of linaclotide. Clinical observations and histopathologic findings in the large intestine (colon, cecum, and rectum) identified the GI system as target organs in both animals euthanized moribund. In other animals in this study which survived until scheduled necropsy, there were no linaclotide-related clinical pathology changes, nor any gross or microscopic findings. Based on mortality, the NOAEL was determined to be 5 mg/kg/day in monkeys administered linaclotide orally for 39 weeks.

**Carcinogenicity:** In 2-year carcinogenicity studies, linaclotide was not tumorigenic in rats at doses up to 3,500 mcg/kg/day or in mice at doses up to 6,000 mcg/kg/day.

**Genotoxicity:** Linaclotide was not genotoxic in an *in vitro* bacterial reverse mutation (Ames) assay or in the *in vitro* chromosomal aberration assay in cultured human peripheral blood lymphocytes.

**Reproductive and Developmental Toxicology:** Linaclotide had no effect on fertility or reproductive function in male and female rats at oral doses of up to 100 mg/kg/day.

The potential for linaclotide to cause teratogenic effects was studied in rats, rabbits, and mice. Oral administration of up to 100 mg/kg/day in rats and 40 mg/kg/day in rabbits produced no maternal toxicity and no effects on embryo-fetal development. In mice, oral dose levels of at least 40 mg/kg/day produced severe maternal toxicity including death, reduction of gravid uterine and fetal weights, and effects on fetal morphology. Oral doses of 5 mg/kg/day did not produce maternal toxicity or any adverse effects on embryo-fetal development in mice.

**Juvenile Toxicity:** In a range-finding tolerability study, when administered orally for 5 days, linaclotide was tolerated at higher dose levels in juvenile mice when treatment was initiated on Day 21 post-partum compared to Day 14 or Day 7. In mice, younger animals were more sensitive to linaclotide-related mortality. In the definitive GLP 9-week repeated-dose oral toxicity study in juvenile mice initiated on Day 7 post-partum, there was an increase in mortality after administration of 1 or 2 doses of linaclotide at 10 mcg/kg/day through Day 9 post-partum. However the 10 mcg/kg/day dose level was

well tolerated after Day 9 post-partum for the remaining treatment period in surviving juvenile mice, with no linaclotide-related adverse effects or microscopic findings and no effects on the physical development or neurobehavioral assessments. Based on the mortality observed, the NOAEL was determined to be 3 mcg/kg/day in juvenile mice administered linaclotide orally once daily for 9 weeks. The increased sensitivity of juvenile mice to linaclotide may be related to the increased expression of intestinal GC-C receptors in young animals or possibly other factors such as those related to an immature GI system (see [2 CONTRAINDICATIONS](#), [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#), and [Special Populations and Conditions](#)].

## **PATIENT MEDICATION INFORMATION**

### **READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE**

**PrCONSTELLA®**

#### **Linacotide Capsules**

Read this carefully before you start taking CONSTELLA and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about CONSTELLA.

#### **Serious Warnings and Precautions**

- CONSTELLA must not be used in children under 6 years of age. This is because children can get diarrhea which can be severe. This can seriously harm a child less than 6 years of age.
- CONSTELLA is not recommended for use in children and adolescents between 6 and 18 years of age. It is not known if CONSTELLA is safe in children and adolescents between 6 years and 18 years of age. It may harm them.

#### **What is CONSTELLA used for?**

##### **CONSTELLA is used to treat the following conditions in adults:**

- Irritable bowel syndrome with constipations (IBS-C).
- Chronic idiopathic constipation (CIC). “Idiopathic” means the cause of the constipation is unknown.

#### **How does CONSTELLA work?**

Constella works by attaching to a receptor in your gut called guanylate cyclase C. This relieves abdominal pain and allows liquid to enter the gut. This in turn helps make bowel movements occur more often and makes them softer. It can also reduce bloating and discomfort. Bowel symptoms may improve in 1 week but pain and discomfort may take longer.

#### **What are the ingredients in CONSTELLA?**

Medicinal ingredients: linacotide

Non-medicinal ingredients:

145 mcg and 290 mcg capsules: calcium chloride dihydrate, gelatin, hypromellose, iron oxide black, iron oxide yellow, L-leucine, microcrystalline cellulose, shellac glaze, and titanium dioxide.

72 mcg capsules: calcium chloride dihydrate, gelatin, L-histidine, iron oxide black, iron oxide yellow, microcrystalline cellulose, polyvinyl alcohol, shellac glaze, talc, titanium dioxide.

#### **CONSTELLA comes in the following dosage forms:**

Capsules: 72 mcg, 145 mcg and 290 mcg of linacotide.

**Do not use CONSTELLA if:**

- You are allergic to linaclotide.
- You are allergic to any of the other ingredients in CONSTELLA or to a component of the container (see **What are the ingredients in CONSTELLA?**).
- You have an intestinal obstruction which is a condition where your bowel is blocked.

Children under 6 years of age must not take CONSTELLA. This is because it is unsafe in children less than 6 years of age.

**To help avoid side effects and ensure proper use, talk to your healthcare professional before you take CONSTELLA. Talk about any health conditions or problems you may have, including if you:**

- are pregnant, think you may be pregnant, or plan to become pregnant. It is not known if CONSTELLA will harm your unborn baby.
- are breast-feeding or planning to breastfeed. Although CONSTELLA is not expected to pass into your breast milk, you and your healthcare professional should decide if you will take CONSTELLA and breastfeed.

Other warnings you should know about:

CONSTELLA can cause diarrhea. Mild to moderate diarrhea often begins within the first two weeks of taking CONSTELLA. Stop taking CONSTELLA and call your doctor right away if you get **severe diarrhea** (persistent watery stools) during treatment with CONSTELLA.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.**

Your doctor or pharmacist will tell you if it is safe to take CONSTELLA with your other medicines. Do not start any medicine while taking CONSTELLA without talking to your healthcare provider first.

**How to take CONSTELLA:**

- Take CONSTELLA exactly as your doctor tells you to take it.
- Take CONSTELLA once a day on an empty stomach, at least 30 minutes before your first meal of the day.
- Swallow the capsule whole with water. Do not chew the capsule. Adults who have difficulty swallowing can open the capsules and sprinkle the contents over applesauce or mix the contents with water before swallowing.

It is not known if CONSTELLA can be sprinkled with other foods or liquids. If you must do this, sprinkle on applesauce or in water.

To take with applesauce:

- Open the CONSTELLA capsule and sprinkle all of the beads onto 1 teaspoon of room temperature applesauce in a clean container.
- Swallow all of the CONSTELLA beads and applesauce right away. Do not keep the applesauce for future use.
- Do not chew the CONSTELLA beads.

To take with water:

- Open the CONSTELLA capsule and pour all of the beads into a clean cup with 30 mL of room temperature bottled water.
- Gently swirl the beads and water for at least 20 seconds.
- Swallow all of the CONSTELLA beads and water mixture right away. Do not keep the mixture for future use.
- Add another 30 mL of water to the cup, swirl for at least 20 seconds and swallow right away.
- The medicine is coated on the beads and dissolves in water so you will get the full dose even if some beads are left in the cup.

To take in a nasogastric or gastric feeding tube:

- Open the CONSTELLA capsule and pour all of the beads into a clean cup with 30 mL of room temperature bottled water.
- Gently swirl the beads and water for at least 20 seconds.
- Draw-up the bead-water mixture into an appropriately sized catheter-tipped syringe. Your doctor should tell you the appropriate size for your dose.
- Remove the cap from the syringe, insert the tip of the syringe into the nasogastric tube or gastric feeding tube and push the plunger all the way in to give the dose.
- After giving the CONSTELLA dose, flush the nasogastric or gastric tube with at least 10 mL of water.
- Add another 30 mL of water to the cup and repeat the process.
- The mixture of beads and water should be used right away. Do not keep for future use.
- It is not necessary to flush all the beads through to get the full dose.

The first meal of the day can be consumed 30 minutes after dosing with CONSTELLA. **Usual dose:**

**IBS-C:** Take 290 mcg orally once a day, at least 30 minutes before your first meal.

**CIC:** Take 145 mcg orally, once a day, at least 30 minutes before your first meal. Your doctor may prescribe a dose of 72 mcg instead depending on your response.

#### **Overdose:**

If you think you, or a person you are caring for, have taken too much CONSTELLA, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

#### **Missed Dose:**

If you miss a dose of CONSTELLA, skip that dose. Do not take two capsules to make up the missed dose. Instead, wait until the next time you are supposed to take it and then take your next dose at the normal time.

#### **What are possible side effects from using CONSTELLA?**

These are not all the possible side effects you may have when taking CONSTELLA. If you experience any side effects not listed here, tell your healthcare professional.

The most common side effects reported with CONSTELLA are:

- Diarrhea
- Passing gas
- Abdominal pain
- Swelling, or a feeling of fullness or pressure in your abdomen (bloating)
- Nausea
- Vomiting
- Fatigue
- Stomach flu
- Indigestion

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
<b>UNCOMMON</b>			
Severe diarrhea (persistent watery stools): watery stools that do not go away.			✓
<b>RARE</b>			
New or worsening abdominal pain not typical of your IBS-C or CIC symptoms			✓

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

#### Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

*NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.*

#### Storage:

- Store CONSTELLA at room temperature between 15°C and 25°C.
- Keep CONSTELLA in the bottle that it comes in.



- The CONSTELLA bottle contains a desiccant packet to help keep your medicine dry (protect it from moisture). Do not remove the desiccant packet from the bottle.
- Keep the container of CONSTELLA tightly closed and in a dry place.

Keep out of reach and sight of children.

**If you want more information about CONSTELLA:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website:  
<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>; the manufacturer's website [www.allergan.ca](http://www.allergan.ca), or by calling 1-800-668-6424.

This leaflet was prepared by Allergan Inc.

Last Revised: JUL 26, 2022